News
13.000 Punkte im Dax – und dann?
13.000 Punkte im Dax sind zum Greifen nahe und jeder wartet gespannt, wann genau die Marke überschritten wird. Was passiert, wenn die Schwelle überschritten wird? Befinden wir uns nicht schon....
202 Million Americans Disapprove of Republicans' Handling of Healthcare Reform, Survey Shows
There has arguably not been a more hot-button issue on Capitol Hill this year than healthcare reform, and it's not hard to understand why. Heading into the Oval Office, Donald Trump had pledged....
Roundtable: 1 Stock Retirees Should Consider
Time magazine declares that "70 is the new 50." And just because you're retired doesn't mean it's time to stop investing. In fact, retirement may be the best time to invest in stocks. Seriously,....
What's Behind AstraZeneca's September Rebound?
After a tough couple of months, British pharma giant AstraZeneca (NYSE: AZN) actually saw its shares rise by a healthy 12.5% last month, according to data from S&P Global Market Intelligence.....
3 High-Yield Healthcare Stocks
Picking solid high-yield dividend stocks can be tricky. Most companies that offer an elevated yield, after all, tend to do so because of a fundamental weakness in their underlying business. Our....
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin just might be the most controversial topic in the investing world. Supporters think the cryptocurrency has the potential to disrupt the financial industry. They also point to bitcoin's....
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
"Dividend Aristocrat" just has a nice ring to it, doesn't it? The "dividend" part sounds great because it means a stock is going to pay you to own it. "Aristocrat" conveys nobility, an elite....
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way,....
3 Drug Stocks That Soared This Week: Are They Buys?
Most investors would be quite happy to get a 20% return over the course of a year. Of course "happy" wouldn't begin to describe the feeling of getting an even better return than that in just a....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Should You Sell Celgene Stock Following an Analyst Downgrade?
Celgene Corp.'s (NASDAQ: CELG) is arguably one of the globe's most successful biotech companies, yet analysts at investment researcher Morgan Stanley cut their rating on the company from equal....
Why EXACT Sciences Corporation Jumped 13.2% in September
Shares of EXACT Sciences (NASDAQ: EXAS), a diagnostics company focused on colon cancer, rose more than 13% in September, according to data from S&P Global Market Intelligence. While it was a....
Why Glaukos Corp. Stock Sank 12.8% in September
After management decided to dial back revenue expectations for 2017, shares of Glaukos (NYSE: GKOS), a medical device maker focused on diseases of the eye, tumbled 13% in September, according to....
Here's Why Alnylam Pharmaceuticals Rallied 32.7% in September
Powered by encouraging phase 3 results for an important pipeline drug, shares of clinical-stage biotech Alnlyam Pharmaceuticals (NASDAQ: ALNY) , which focuses on RNAi treatments, gained 33% in....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
What Caused Sarepta Therapeutics to Rally 12.6% in September
After reporting early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics (NASDAQ: SRPT) jumped 12.6% last month,....
3 High-Yield Billionaire Stocks
Billionaire investors know a thing or two about picking stocks. That's why we Fools like to scan our favorite investors' holdings every couple of months to see what they have been buying and....
A Generic Drug Face-Off Sends Mylan Soaring 19%
After the Food and Drug Administration surprisingly gave a green light to the company's Copaxone knockoff, shares in Mylan Inc. (NASDAQ: MYL) are surging 19.5% higher today at 11:30 a.m. EDT. Teva....